Corcept Therapeutics

This study is testing whether an investigational drug called miricorilant can reduce liver fat and improve liver health in adults with NASH/MASH, a serious form of fatty liver disease. About 175 participants will receive either the drug or a placebo for 24 or 48 weeks. The main g…

This study aims to evaluate the long-term safety of the drug relacorilant for people with Cushing syndrome. It is open to 125 patients who successfully completed a previous relacorilant trial and whose doctor believes they would benefit from continuing treatment. Participants wil…

This early-stage study aims to understand how the body absorbs two new tablet versions of the experimental drug miricorilant, compared to an older version. It will involve 18 healthy adult volunteers who will take the different pills in a specific order. The main goal is to measu…